← Coach — Ophthalmology · Coach — Eye · Coach hub

Coach — Arterial and Venous Occlusions: One Failure, Two Scars

Arterial and venous occlusions, in this view, are two scars of one failure: a vessel wall that can no longer keep nitric oxide coupled and its mitochondria competent.

The eye is a high-resolution prototype of vascular failure. Its arteries and veins are small, share sheaths where they cross and inside the optic nerve, and serve tissue that reports injury within minutes as lost vision. Blockages of the central or branch retinal artery, and of the central or branch retinal vein, work like clinical microscopes. They show, in a single vascular bed, the same upstream processes that later declare themselves as coronary occlusion, stroke, deep-vein thrombosis, or pulmonary embolism.

This hypothesis argues that arterial and venous occlusions share one metabolic root: the progressive loss of coupled endothelial nitric oxide and mitochondrial competence in the vessel wall. The dramatic events, an embolus, a clot, a compressed vein, a hemorrhage, an infarction, are downstream expressions of that root, not independent diseases.

Why two separate models fall short

Standard teaching separates the two by flow and by the kind of clot. Arterial events happen under high shear, driven by plaque rupture or an embolus, and form platelet-rich “white” clots that starve tissue of oxygen. Venous events happen under low shear and follow Virchow’s triad, stasis, injury or activation of the vessel lining, and a tendency to clot, forming “red” clots that back up pressure and leak. In the eye the split is sharp: retinal artery occlusion behaves as an ocular stroke with high later vascular risk, while retinal vein occlusion is more often managed as a local swelling problem, though it too tracks cardiovascular risk factors.

These descriptions are accurate as far as they go. They do not explain why the same middle-aged patient can develop both, why endothelial dysfunction appears years before either event, or why some lean people with efficient mitochondria carry high apoB without plaque while insulin-resistant people progress at modest particle numbers. On this hypothesis, a single upstream failure of energy-flux management accounts for more of the data with fewer entities.

Nitric oxide as flux manager

Nitric oxide is the short-range flux manager. It opens feed arteries in response to shear, rations oxygen use at the end of the respiratory chain so nearby mitochondria do not monopolize it, and keeps white cells, platelets, and smooth muscle quiet so the lumen stays open. When eNOS, the enzyme that makes it, is coupled and mitochondria oxidize cleanly, high energy flux is possible without proportional damage. When superoxide uncouples the enzyme, the manager becomes a source of peroxynitrite, and the wall begins the program that ends in plaque, or in a vein that can no longer tolerate ordinary compression and stasis.

In arteries, that failure shows up as atherosclerosis: a leakier lining, apoB particles retained and oxidized, struggling macrophages, foam cells, and eventually plaque. The final blockage may be a rupture with a clot on top or an embolus from a distant unstable site. The retina makes the endpoint dramatic. A blockage in the central retinal artery takes vision at once, and over the next hours the retina turns pale around a cherry-red spot, because the inner retina has almost no collateral reserve.

In veins, the same weakened lining meets different physics. Where a retinal artery crosses a vein, the two share a sheath, so a stiffening artery narrows the vein, produces turbulent flow, and injures its lining. In the lamina cribrosa, at the optic nerve head, the central retinal artery and vein are enclosed together, and elevated eye pressure further impedes venous outflow. On a lining already sticky and clot-prone from nitric oxide loss, ordinary compression and modest hyperviscosity are enough to start a clot. The resulting congestion raises pressure, breaks the blood-retinal barrier, and produces the hemorrhages, edema, and secondary ischemia of retinal vein occlusion.

So the two pathways share the upstream lesion and diverge only in the geometry and shear that turn it into a blockage. Clotting disorders, dehydration, and hormonal effects on clotting act as precipitants on a prepared surface; on this view they are not the root.

Ferritin as a sentinel

Ferritin is usually read as a storage ledger of iron. A metabolic reading treats it as a sentinel. Iron is indispensable for the respiratory chain and dangerous as a catalyst of oxidant damage. When cells sense rising oxidants or inflammation, they make more ferritin to lock iron away. In chronic low-grade oxidant and inflammatory states, the same states that uncouple eNOS, that containment becomes persistent: ferritin rises while the iron actually available for blood cells and new mitochondria is restricted.

That matters for clotting. Stressed endothelium expresses more adhesion molecules and tissue factor, iron deficiency is associated with higher platelet counts and endothelial dysfunction, and metabolic hyperferritinemia is common in insulin resistance and fatty liver. Ferritin is not the cause of occlusion, the hypothesis says; it is a readable signal that the body is containing an oxidant threat. Resolving the threat, through fuel quality, shear, and circadian amplitude, is proposed to lower the drive to lock iron away.

The eye as prototype and canary

Retinal vessels are an experimental system that evolution and clinical medicine have already built. Branch retinal vein occlusion almost always occurs at an arteriovenous crossing, usually where the artery lies over the vein, and central retinal vein occlusion occurs where the vessels share the fibrous envelope of the lamina cribrosa. Both sites concentrate the mechanical cost of a stiffening artery onto the vein.

Both retinal artery and vein occlusions rise with age and with the classic metabolic risk factors. Artery occlusions carry a clearer short-term stroke and cardiac risk because they more often come from emboli from the same sources that threaten the brain. Vein occlusions track hypertension, glaucoma, and the metabolic syndrome more tightly, with a lower but still elevated systemic risk. In younger patients without the usual risk factors, clotting disorders such as antiphospholipid antibodies or factor V Leiden become visible because the precipitant must be stronger.

The optic nerve head adds a further watershed. Non-arteritic anterior ischemic optic neuropathy (NAION) is, on this hypothesis, an energy failure of the front of the optic nerve in a crowded disc: perfusion reserve collapses, transport along the nerve fibers fails, the disc swells in a tight scleral canal, and vision is often permanently cut. This anatomy is especially sensitive to sudden changes in perfusion pressure, nocturnal blood pressure, viscosity, and nutrient delivery, and its axons are lifelong.

Dashboard drugs and the optic nerve

Statins block HMG-CoA reductase at the mouth of the mevalonate pathway, which makes cholesterol but also a mobile electron carrier of the respiratory chain. In secondary prevention they reduce plaque events, and some observational studies associate their use with lower rates of retinal vascular occlusion and fewer later cardiovascular events after either kind of occlusion. These benefits are real. On this hypothesis they come mainly from lowering apoB, stabilizing plaque, and calming inflammatory cascades, not from restoring energy capacity in the vessel wall or in high-demand axons. That is sophisticated dashboard work.

GLP-1 receptor agonists override appetite circuits and gastric emptying, and weight, glucose, and often MACE improve. They do not repair electron-transport function, a substantial fraction of the weight lost is lean mass unless protein and mechanical loading are protected, and rapid glycemic change can alter small-vessel flow. As study information: observational signals link semaglutide to roughly two-fold increased NAION risk, and the absolute excess is small, on the order of one extra case per ten thousand person-years in some estimates. The hypothesis reads this as a low-absolute-incidence tail risk inside a beneficial average, concentrated where crowded discs, sleep apnea, nocturnal hypotension, rapid early weight and A1c decline, high-intensity statin, and low baseline muscle coincide.

Neither drug is dismissed. Both can buy time by unloading the vessel wall and lowering inflammatory drive. The hypothesis asks that the time be used to restore the engine, not to call the patches health. Sudden vision loss in one eye on the combination is an energy emergency, not a curiosity. Sudden loss of vision in one eye, even if it clears, is an emergency: go to an emergency department right away, because a blocked eye artery is treated like a stroke. In anyone over 50, new headache, jaw pain when chewing, or scalp tenderness with vision loss can mean giant cell arteritis, which needs treatment the same day to protect the other eye. Anyone on semaglutide or a similar drug who has sudden vision loss should also tell the prescribing physician without delay.

The same story in heart, brain, and leg

The same architecture operates at larger scale. Coronary occlusion is the cardiac expression of the arterial pathway. Cerebral arterial infarction, a stroke, follows the identical sequence in the carotid or intracranial arteries. Peripheral arterial occlusion is the same process in the larger arteries that serve skeletal muscle. In each case the final thrombus is the event that brings the patient to attention; the decades-long preparation of the wall is the disease.

Venous thromboembolism follows the low-shear pathway. Immobility, surgery, or pregnancy supplies stasis; cancer, inflammation, or hormonal states supply hypercoagulability; and a prepared lining supplies the third element of Virchow’s triad. Obesity and insulin resistance appear in both arterial and venous risk tables because, on this view, they are systemic expressions of the same cellular energy failure.

Where EnSurf fits

If both kinds of occlusion are downstream of mitochondrial and nitric oxide failure, the hypothesis puts the engine first. Fuel that mitochondria oxidize cleanly reduces electron leak and the superoxide that uncouples eNOS. Fasting is not safe for everyone. People taking insulin or other blood-sugar-lowering drugs, people with a primary mitochondrial disease or a heart-rhythm problem, and anyone pregnant should fast only under their physician’s care, and fasting should never mean going short on fluids, since dehydration thickens the blood. Circadian alignment, morning light, consistent sleep, and dim evenings, supports the daily rhythm of eNOS and mitochondrial quality control. Strength and conditioning supply the repeated laminar shear that switches on eNOS and writes more of it over time. Grip strength and functional capacity remain practical surrogates of the whole stack.

Prescription drugs keep defined places as bridges, not substitutes: statins in secondary prevention and advanced disease, antiplatelet agents in the high-shear arterial phase, anticoagulation when a physician finds atrial fibrillation or a clotting disorder that calls for it, PDE5 inhibitors with their rare reported association with NAION in crowded discs, and GLP-1 agonists in selected patients. Each is a decision for you and your physician; nothing here is a regimen. Talk with your own physician before changing anything.

Arterial and venous occlusions, on this hypothesis, are not two diseases that happen to share risk factors. They are two geometric expressions of one metabolic failure. Atherosclerosis is the high-shear scar, venous thrombosis is the low-shear scar, and the eye makes the sequence visible before it declares itself in the heart, brain, or leg, with the optic nerve head as the canary.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

Related: Eye · Hypertension · Cardiology · GLP-1 and Statins · Brain · Ophthalmology. Full version: the extended report, The Metabolic Hypothesis of Arterial and Venous Occlusions.

See the notice at the top of this page. Working hypothesis, not medical advice.